CD2 through its interaction with the cell surface protein, CD58, has critical functions for the activation of T cells and ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

What's the secret to a healthier diet? Discover 5 powerful root vegetables that boost immunity, fight inflammation, and support overall wellness.

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

The Switch has been an enormous success — it’s the third-best-selling console of all time, behind only the PlayStation 2 and Nintendo’s own DS handheld — which presents both a big ...

Here are all the latest rumors, plus plenty of carefully considered speculation, about the Nintendo Switch 2. Although the Nintendo Switch 2 has yet to be officially announced, Nintendo has ...

When is the Ark 2 release date? Ever since the Ark 2 announcement at The Game Awards 2020, we’ve been looking forward to learning more about the upcoming dinosaur-themed survival game.

with IL-7 and IL-15 widely preferred over IL-2, to prevent differentiation. 34 Supplementation with IL-21 has also been shown enhance the enrichment and expansion of less differentiated T-cell ...

Consistent with this, chemerin caused no difference in cytokine secretion by activated T cells. Specifically, the concentrations of IL-2, IL-17A, IFNγ, and TNFα were similar between groups. Overall, ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance. Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMN ...

An investigator has posted data on Coya Therapeutics’ COYA 301, linking the IL-2 asset to improvements in biomarkers and cognition on secondary and exploratory endpoints in a small Alzheimer’s ...